| Dr Suzanne Marie Light, PHARMD | |
|
20 13th St, Havre, MT 59501-5222 | |
| (406) 262-1756 | |
| (406) 262-1628 |
| Full Name | Dr Suzanne Marie Light |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 20 13th St, Havre, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548360183 | NPI | - | NPPES |
| RPH 48224 | Other | CA | CALIFORNIA STATE LICENSE |
| 033-0003635 | Other | VT | VERMONT STATE LICENSE |
| 5204 | Other | MT | MONTANA STATE LICENSE |
| 10929 | Other | AZ | ARIZONA STATE LICENSE |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Suzanne Marie Light, PHARMD 3233 Clear Creek Rd, Havre, MT 59501-8159 Ph: (406) 265-2888 | Dr Suzanne Marie Light, PHARMD 20 13th St, Havre, MT 59501-5222 Ph: (406) 262-1756 |
News Archive
The Patient-Centered Outcomes Research Institute Board of Governors today approved $61.3 million for a slate of several infrastructure projects that will support the activities of eight Clinical Research Networks to implement the next phase of PCORnet, the National Patient-Centered Clinical Research Network.
Scientists at the IFOM-IEO Campus have revealed the function of a protein that is indispensable for passing on an accurate copy of the genome from mother to daughter cells. This study, published in Cell, opens up new avenues of research to reduce the toxicity of chemotherapy in the treatment of cancer.
Prostate cancer cells require androgens including testosterone to grow. A recent review in the British Journal of Urology International describes new classes of drugs that target androgens in novel ways, providing alternatives to the traditional methods that frequently carry high side effects.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate (NHP) lethal aerosol exposure model.
Not only does the type of flu virus affect a patient's outcome, but a new research report appearing in the Journal of Leukocyte Biology suggests that the number of viruses involved in the initial infection may be important too.
› Verified 1 days ago
Dennis Heggem, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3510 Us Highway 2 W, Havre, MT 59501 Phone: 406-262-9174 | |
Larry Wayne Fangsrud, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3180 Hwy 2 W, Kmart Pharmacy, Havre, MT 59501 Phone: 406-265-1854 Fax: 406-265-4647 | |
Donald Harper, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3510 Highway 2 West, Havre, MT 59501 Phone: 406-262-9176 | |
Mr. Kyle Austin, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 38504 Us Highway 2, Havre, MT 59501 Phone: 406-262-3098 | |
Alexa Christian, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 730 1st St, Havre, MT 59501 Phone: 406-265-1229 Fax: 406-265-3256 | |
Darin Lee Miller, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 521 4th St, Havre, MT 59501 Phone: 406-395-6906 Fax: 406-395-5996 | |
Patrick A Thorsen, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 20 13th St W, Havre, MT 59501 Phone: 406-262-1702 |